Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors
Boston Scientific (BSX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BSX crossed above the 200-day moving average, suggesting a long-term bullish trend.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Is Boston Scientific (BSX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Boston Scientific (BSX) could produce exceptional returns because of its solid growth attributes.
What's Behind Boston Scientific's Optimism for Urology Growth?
BSX sees stronger 2026 prospects for Urology, powered by Axonics integration, innovation and global Stone Management momentum.
Boston Scientific Sustains EP Momentum in Q3: Is More Upside Ahead?
BSX's Q3 EP sales soar 63% on FARAPULSE momentum, FDA label expansion and rising global adoption.
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.
Boston Scientific Q3: Operational Improvements Warrant An Upgrade To A Buy
Boston Scientific delivered strong Q3 results, with 20% revenue growth and beats on both top and bottom lines, prompting a rating upgrade to Buy. BSX's cardiovascular and MedSurg segments, driven by innovations like WATCHMAN and Farapulse, are fueling impressive growth and margin expansion. Management raised 2025 guidance, highlighting robust product demand, successful M&A strategy, and promising pipeline, especially in chronic pain and stroke prevention.
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors
After reaching an important support level, Boston Scientific (BSX) could be a good stock pick from a technical perspective. BSX surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Boston Scientific (BSX) Recently Broke Out Above the 50-Day Moving Average
From a technical perspective, Boston Scientific (BSX) is looking like an interesting pick, as it just reached a key level of support. BSX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q3 2025 Earnings Call October 22, 2025 8:00 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President & CEO Jonathan Monson - Executive VP & CFO Ken Stein - Senior VP & Global Chief Medical Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Joanne Wuensch - Citigroup Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Michael Polark - Wolfe Research, LLC Travis Steed - BofA Securities, Research Division Patrick Wood - Morgan Stanley, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Christopher Pasquale - Nephron Research LLC Pito Chickering - Deutsche Bank AG, Research Division Presentation Operator Good morning, and welcome to the Boston Scientific Third Quarter 2025 Earnings Call. [Operator Instructions] Please note this event is being recorded.
